ARID2 and hepatocellular carcinoma: Tumorigenic consequences of ARID2 dysregulation are multifactorial: (1) Transcriptomic profiling reveals significant ARID2 downregulation in HCC tissues, where it physically interacts with E2F1 to attenuate RNA Polymerase II recruitment at cyclin D1 (CCND1) and cyclin E1 (CCNE1) promoters.